A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)
Purpose
The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD). Before giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.
Condition
- Healthy
Eligibility
- Eligible Ages
- Between 18 Years and 55 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Is in good health - Has a body mass index (BMI) ≥ 18 and ≤ 32 kg/m^2
Exclusion Criteria
- Has history of cancer (malignancy) - Has a history of significant multiple and/or severe allergies
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental MK-1403 formulation (FM) 1 + additive, Fed |
MK-1403 FM 1 + additive tablet administered once orally at study dose after a high-fat meal. |
|
|
Experimental MK-1403 FM1 + additive, Fasted |
MK-1403 FM1 + additive tablet administered once orally at study dose in a fasted state. |
|
|
Experimental MK-1403 FM2 + additive, Fed |
MK-1403 FM2 tablet + additive administered once orally at study dose after a high-fat meal. |
|
Recruiting Locations
Qps-Mra, Llc
Miami, Florida 33143
Miami, Florida 33143
Contact:
Study Coordinator
Study Coordinator
More Details
- Status
- Recruiting
- Sponsor
- Merck Sharp & Dohme LLC